{"id":53671,"date":"2026-01-15T22:29:01","date_gmt":"2026-01-15T21:29:01","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/01\/15\/elderly-onset-rheumatoid-arthritis-as-a-distinct-entity-mechanisms-manifestations-and-treatment\/"},"modified":"2026-01-15T22:29:01","modified_gmt":"2026-01-15T21:29:01","slug":"elderly-onset-rheumatoid-arthritis-as-a-distinct-entity-mechanisms-manifestations-and-treatment","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/01\/15\/elderly-onset-rheumatoid-arthritis-as-a-distinct-entity-mechanisms-manifestations-and-treatment\/","title":{"rendered":"Elderly-onset rheumatoid arthritis as a distinct entity: mechanisms, manifestations, and treatment"},"content":{"rendered":"<div>\n<p><b>Curr Opin Immunol<\/b>. 2026 Jan 13;99:102721. doi: 10.1016\/j.coi.2025.102721. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Elderly-onset rheumatoid arthritis (EORA), defined as onset at \u226560 years, is a clinically distinct and increasingly prevalent subset of rheumatoid arthritis (RA). This review synthesizes evidence that EORA is not merely late-onset RA but a pathogenically unique entity, driven by immune aging, inflammaging, and other mechanisms like defective immunosuppressive system, age-related somatic mosaicism, and dysbiosis. It frequently presents with heterogeneous features such as acute large-joint involvement and polymyalgia symptoms, often leading to diagnostic delays. Despite similar initial activity to young-onset RA, EORA follows a more aggressive course with severe joint destruction and significant comorbidities. Treatment with conventional disease-modifying antirheumatic drugs is complicated by polypharmacy and high adverse event risks, often leading to undertreatment. A shift to geriatric-centered care, with comprehensive assessment and tailored treat-to-target strategies, is therefore imperative. This review underscores the need to recognize EORA&#8217;s unique pathophysiology and clinical profile to improve diagnosis, therapy, and outcomes for this growing population.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41534450\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=8900118&amp;ff=20260115162900&amp;v=2.18.0.post22+67771e2\">41534450<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.coi.2025.102721\">10.1016\/j.coi.2025.102721<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Curr Opin Immunol. 2026 Jan 13;99:102721. doi: 10.1016\/j.coi.2025.102721. Online ahead of print. ABSTRACT Elderly-onset rheumatoid arthritis (EORA), defined as onset at \u226560 years, is a clinically distinct and increasingly prevalent subset of rheumatoid arthritis (RA). This review synthesizes evidence that EORA is not merely late-onset RA but a pathogenically unique entity, driven by immune aging, &#8230; <a title=\"Elderly-onset rheumatoid arthritis as a distinct entity: mechanisms, manifestations, and treatment\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/15\/elderly-onset-rheumatoid-arthritis-as-a-distinct-entity-mechanisms-manifestations-and-treatment\/\" aria-label=\"Read more about Elderly-onset rheumatoid arthritis as a distinct entity: mechanisms, manifestations, and treatment\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[59,42],"tags":[],"class_list":["post-53671","post","type-post","status-publish","format-standard","hentry","category-current-opinion-in-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/53671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=53671"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/53671\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=53671"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=53671"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=53671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}